FDA.reportPublic FDA data

trastuzumab-strf 21 MG/ML Injectable Solution [Hercessi]

RxCUI
2700731
RxNorm name
trastuzumab-strf 21 MG/ML Injectable Solution [Hercessi]
Display name
trastuzumab-strf 21 MG/ML Injectable Solution [Hercessi]
Full name
trastuzumab-strf 21 MG/ML Injectable Solution [Hercessi]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:38:51

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761346Hercessitrastuzumab-strf351(k) BiosimilarRx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
285d2142-5bfa-401c-9246-7de21c4451afHERCESSI 420 MG in 20 ML Injectable Solution [PSN] · trastuzumab-strf 21 MG/ML Injectable Solution [Hercessi] [SBD] · Hercessi 21 MG/ML Injectable Solution [SY] · Hercessi 420 MG per 20 ML Injectable Solution [SY]44These highlights do not include all the information needed to use HERCESSI safely and effectively. See full prescribing information for HERCESSI. HERCESSI TM (trastuzumab-strf) for injection, for intravenous use Initial U.S. Approval: 2024 HERCESSI (trastuzumab-strf) is biosimilar* to HERCEPTIN (trastuzumab).20250321